A NEW surgical procedure in the brain could be a cure for drug addicts
without injuring the vital organ, local medical authorities said
yesterday.
With the new method, doctors from Renji Hospital managed to
help a 24-year-old patient with a five-year history of drug abuse to remain
clean for more than six years without a relapse. Usually, over 95 percent of
addicts relapse within six months after quitting, due to the strong
psychological dependency.
It is said to be the world's first reported
successful case of treating drug addiction with a form of acupuncture through
electrical stimulation in the brain, according to the latest edition of
Biological Psychiatry, an international academic journal.
Doctors said
the article is a good reference for health authorities to regulate and restart
surgical treatment for drug addiction in China after the Ministry of Health
banned a controversial surgical procedure that involved removing a small portion
of the patient's brain, in November 2004.
"Unlike the surgery where a
part of the brain is removed, our treatment is minimally invasive and just
stimulates a part of the brain to block the addict's drug-induced psychological
dependency," said Dr Zhou Hongyu of Renji Hospital's neurosurgery department.
"Similar therapy has been used for many diseases, like Parkinson's, around the
world and in China."
During the surgery, doctors input two needles as
electrodes into the brain, at a certain position, to stimulate relative tissues
to stop people's desire to use drugs.
The two needles are connected by
wires to a remote control placed in the patient's chest and takes effect after
the strength and frequency of the stimulation are set.
"Compared with
the previous banned surgery, this treatment doesn't remove any brain tissues,"
Zhou said. "The process is even safer than the one used to treat Parkinson's
disease, as the position where we place the needles is not close to any major
functional tissues in the brain while the position of the needles for treating
Parkinson's is close to the part which controls mobility."
But the new
therapy is still in an experimental stage; wide adoption will need the health
ministry's approval.